Join Our Team
SOTIO Biotech is an innovative, clinical-stage biopharmaceutical company developing targeted cancer therapies with first-in-class and best-in-class potential. We are looking for talented, ...
Business Development
SOTIO aims to become a diverse oncology company that develops early stage candidates into marketed targeted therapies. We seek to add to our portfolio projects that are at advanced preclinical or clinical stages.
SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma
First-in-human study of SOT106 to be initiated in second half of 2026, advancing a differentiated LRRC15 ADC toward early clinical signal; SOTIO Biotech, a clinical-stage biopharmaceutical ...
SOTIO Programs
Immunocytokines
SOTIO’s immunocytokine platform is designed to preferentially activate immune cells in the tumor microenvironment by targeted delivery of a cytokine agonist.
Antibody-Drug Conjugates - SOT106
SOTIO is developing SOT106, an ADC against leucine-rich repeat containing 15 (LRRC15). SOT106 is a novel ADC based on SOTIO Biotech’s proprietary antibody and LigaChem Biosciences (former LegoChem) industry-leading ConjuAllTM ADC platform technology.
Antibody-Drug Conjugates - SOT109
SOT109 is an ADC candidate targeting cadherin-17 (CDH17), a protein homogenously overexpressed in more than 90% of colorectal cancers (CRC) and abundantly expressed in other GI cancers, including gastric, pancreatic, and esophageal cancers.
Contacts
Boston
Prague
Basel
Amsterdam
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
